Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Prototype development project for pilot studies with Singapore

Reference number
Coordinator Cognes Medical Solutions AB
Funding from Vinnova SEK 86 375
Project duration January 2025 - September 2025
Status Ongoing
Venture Cooperation between Sweden och Israel
Call Planning grants for collaborations with small, smart countries; Singapore or Israel

Purpose and goal

The purpose of this project is to explore collaboration between two Swedish SMEs and one Singapore SME to determine feasibility and plan our main proposal which is to develop an ISO compliant prototype of the Cognes Dementia Screening Tool (CDST) for use in pilot studies. Starting a partnership with Singapore not only opens the doors to other strategic relationships in Singapore, it is a potential market entry gateway towards the rest of Asia Pacific.

Expected effects and result

The expected results of this project is to establish a long term partnership between Swedish and Singaporean SMEs for future R&D projects. This entails a deeper understanding of each other´s expertise and how each can contribute. Having a good connection enables us to explore future collaborations and opportunities together in an efficient manner.

Planned approach and implementation

Virtual meetings are conducted to brainstorm the overview of the prototype including information architecture, focusing on the screening process and ensuring logical flow for the user. Market survey including research for design development such as iterative user research (interviews) are conducted to discuss prototype versions. The team actively seeks and identifies open calls that will be most relevant to the project for funding.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 16 April 2025

Reference number 2024-03873